Pharma Flat At Akzo Nobel In 3rd Qtr
Pharmaceutical operating income at Akzo Nobel of the Netherlands was 190 million guilders ($112.2 million) in the third quarter of 1996, a marginal 1% increase on the year-earlier quarter. Turnover was ahead 3.1% to 962 million guilders.
The group said that the negative effects of last year's scientific debate on oral contraceptives (Marketletters passim), and the extra costs for new product launches at subsidiary Organon were offset by higher contributions from the veterinary unit, Intervet, and Diosynth, which specializes in raw materials for the pharmaceutical industry.
The third quarter also had additional costs associated with promising new product launches, such as fertility hormone Puregon (follitropin beta), and an antidepressant, Remeron (mirtazapine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze